We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small...
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR...
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 3.69 | 17.0833333333 | 21.6 | 25.29 | 20.68 | 151968 | 23.23633276 | CS |
4 | 2.41 | 10.5332167832 | 22.88 | 26.34 | 20.68 | 162439 | 23.58654123 | CS |
12 | 1.79 | 7.6170212766 | 23.5 | 26.34 | 18.62 | 249071 | 22.48048331 | CS |
26 | 1.79 | 7.6170212766 | 23.5 | 26.34 | 18.62 | 249071 | 22.48048331 | CS |
52 | 1.79 | 7.6170212766 | 23.5 | 26.34 | 18.62 | 249071 | 22.48048331 | CS |
156 | 1.79 | 7.6170212766 | 23.5 | 26.34 | 18.62 | 249071 | 22.48048331 | CS |
260 | 1.79 | 7.6170212766 | 23.5 | 26.34 | 18.62 | 249071 | 22.48048331 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions